Gyre Therapeutics, Inc. (NASDAQ:GYRE) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its stake in Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 392.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 113,648 shares of the company’s stock after purchasing an additional 90,557 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.12% of Gyre Therapeutics worth $1,425,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of GYRE. WINTON GROUP Ltd bought a new position in shares of Gyre Therapeutics in the second quarter valued at $220,000. Bank of New York Mellon Corp acquired a new position in Gyre Therapeutics during the second quarter worth $218,000. Renaissance Technologies LLC bought a new stake in Gyre Therapeutics during the second quarter worth approximately $166,000. Finally, Rhumbline Advisers acquired a new position in shares of Gyre Therapeutics during the second quarter worth approximately $123,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Stock Up 3.6 %

Shares of GYRE opened at $9.99 on Tuesday. Gyre Therapeutics, Inc. has a 52 week low of $8.26 and a 52 week high of $30.40. The company has a 50-day simple moving average of $13.01 and a 200-day simple moving average of $12.61.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.